Deciphering the apoptotic pathway: All roads lead to death

Immunology and Cell Biology

Volumn 76, Issue 1, 1998, Pages 1-19

  Lincz, Lisa F ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b ROYAL NEWCASTLE HOSPITAL   (Australia)

Author keywords

Antigens; Apoptosis; CD95; Proto oncogene proteins c bcl 2

Indexed keywords

CASPASE; ENZYME; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; HUMAN; NONHUMAN; ONCOGENE; PATHOPHYSIOLOGY; PROTEIN DETERMINATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CAENORHABDITIS ELEGANS; CASPASE 1; CYSTEINE ENDOPEPTIDASES; GRANZYMES; HUMANS; LIGANDS; MODELS, BIOLOGICAL; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CELL SURFACE; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES;

EID: 0031946009     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1998.00712.x     Document Type: Review

References (219)

1. Clarke PGH, Clarke S. Historic apoptosis. Nature 1995; 378: 230.
2. Clarke PG, Clarke S. Nineteenth century research on naturally occurring cell death and related phenomena. Anat. Embryol. (Berl.) 1996; 193: 81-99.
3. Lockshin RA, Williams CM. Programmed cell death. II: Endocrine potentiation of the breakdown of the intersegmental muscles of silkmoths. J. Insect Physiol. 1964; 10: 643.
4. Kerr JFR, Wyllie AH, Currie AH. Apoptosis, a basic biological phenomenon with wider implications in tissue kinetics. Br. J. Cancer 1972; 26: 239-45.
5. Schwartz LM, Osborne BA. Programmed cell death, apoptosis and killer genes. Immunol. Today 1993; 14: 582-90.
6. Martz E, Howell DM. CTL: virus control cells first and cytolytic cells second? DNA fragmentation, apoptosis and the prelytic halt hypothesis (comments). Immunol. Today 1989; 10: 79-86.
7. Schwartz LM, Truman JW. Peptide and steroid regulation of muscle degeneration in an insect. Science 1982; 215: 1420-1.
8. Trump BF, Goldblatt PJ, Stowell RE. Studies of mouse liver necrosis in vitro: Ultrastructural and cytochemical alterations in hepatic parenchymal cell nuclei. Lab. Invest. 1965; 14: 1969-99.
9. Searle J, Lawson TA, Abbott PJ, Harmon B, Kerr JFR. An electron-microscope study of the mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J. Pathol. 1975; 116: 129-38.
10. Wyllie AH, Apoptosis: Cell death in tissue regulation. J. Pathol. 1987; 153: 313-16.
11. Brown DG, Sun XM, Cohen GM. Dexamethasone-induced apoplosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation. J. Biol. Chem. 1993; 268: 3037-9.
12. Peitsch MC, Muller C, Tschopp J. DNA fragmentation during apoptosis is caused by frequent single-strand cuts. Nucleic Acids Res. 1993; 21: 4206-9.
13. Didenko VV, Hornsby PJ. Presence of double-strand breaks with single-base 3′ overhangs in cells undergoing apoptosis but not necrosis. J. Cell Biol. 1996; 135: 1369-76.
14. (2+)-dependent endonuclease associated with apoptosis. J. Immunol. 1996; 156: 922-31.
15. Tounekti O, Belehradek J, Mir LM. Relationships between DNA fragmentation, chromatin condensation, and changes in flow cytometry profiles detected during apoptosis. Exp. Cell Res. 1995; 217: 506-16.
16. Cohen GM, Sun XM, Snowden RT, Dinsdale D, Skilleter DN. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem. J. 1992; 286: 331-4.
17. Oberhammer FA, Pavelka M, Sharma S et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc. Natl Acad. Sci. USA 1992; 89: 5408-12.
18. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res. 1993; 53: 3976-85.
19. Lindahl T. Recognition and processing of damaged DNA. J. Cell Sci. Suppl. 1995; 19: 73-7.
20. Satoh MS, Lindahl T. Role of poly (ADP-ribose) formation in DNA repair. Nature 1992; 356: 356-8.
21. Panzeter PL, Zweifel B, Malanga M, Waser SH, Richard M, Althaus FR. Targeting of histone tails by poly (ADP-ribose). J. Biol. Chem. 1993; 268: 17 662-4.
22. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukaemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note. Cancer Res. 1989; 49: 5870-8.
23. Wang ZQ, Auer B, Stingl L et al. Mice lacking ADPRT and poly (ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev. 1995; 9: 509-20.
24. Takahashi A, Goldschmidt CP, Alnemri ES et al. Inhibition of ICE-related proteases (caspases) and nuclear apoptosis by phenylarsine oxide. Exp. Cell Res. 1997; 231: 123-31.
25. Liu X, Zou H, Slaughter C, Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997; 89: 175-84.
26. Meisenholder GW, Martin SJ, Green DR, Nordberg J, Babior BM, Gottlieb RA. Events in apoptosis: Acidification is downstream of protease activation and BCL-2 protection. J. Biol. Chem. 1996; 271: 16 260-2.
27. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 1992; 148: 2207-16.
28. Schlegel RA, Stevens M, Lumley SK, Williamson P. Altered lipid packing identifies apoptotic thymocytes. Immunol. Lett. 1993; 36: 283-8.
29. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van OM. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-20.
30. Martin SJ, Reutelingsperger CP, McGahon AJ et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 1995; 182: 1545-56.
31. Fadok VA, Savill JS, Haslett C et al. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. J. Immunol. 1992; 149: 4029-35.
32. Schlegel RA, Callahan M, Krahling S, Pradhan D, Williamson P. Mechanisms for recognition and phagocytosis of apoptotic lymphocytes by macrophages. Adv. Exp. Med. Biol. 1996; 406: 21-8.
33. Choe HR, Schlegel RA, Rubin E, Williamson P, Westerman MP. Alteration of red cell membrane organization in sickle cell anaemia. Br. J. Haematol. 1986; 63: 761-73.
34. Casciola RL, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: Implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 1996; 93: 1624-9.
35. Driscoll M. Molecular genetics of cell death in the nematode Caenorhabditis elegans. J. Neurobiol. 1992; 23: 1327-51.
36. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986; 44: 817-29.
37. Shaham S, Horvitz HR. An alternatively spliced C. elegans ced-4 RNA encodes a novel cell death inhibitor. Cell 1996; 86: 201-8.
38. Hengartner MO, Ellis RE, Horvitz HR. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 1992; 356: 494-9.
39. Hengartner MO, Horvitz HR. Activation of C. elegans cell death protein CED-9 by an amino acid substitution in a domain conserved in Bcl-2. Nature 1994; 369: 318-20.
40. Vaux DL, Weissman IL, Kim SK. Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2. Science 1992; 258: 1955-7.
41. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 1993; 75: 641-52.
42. Walker NP, Talanian RV, Brady KD et al. Crystal structure of the cysteine protease interleukin-1 beta-converting enzyme: A (p20/p10)2 homodimer. Cell 1994; 78: 343-52.
43. Wilson KP, Black JAF. Thomson JA et al. Structure and mechanism of interleukin-1-beta converting enzyme. Nature 1994; 370: 270-5.
44. Miura M, Zhu H, Rotello R, Hartwieg EA, Yuan J. Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 1993; 75: 653-60.
45. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405-13.
46. Tsujimoto Y, Cossman J, Jaffe E, Croce C. Involvement of the Bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440-3.
47. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl Acad. Sci. USA 1986; 83: 5214-18.
48. Chen-Levy S, Cleary ML, Membrane topology of the Bcl-2 proto-oncogene protein demonstrated in vitro. J. Biol. Chem. 1990; 265: 4929-33.
49. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigations of the subcellular distribution of the BCL-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum. and outer mitochondrial membranes. Cancer Res. 1993; 53: 4701-14.
50. Vaux D, Cory S, Adams J, Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-2.
51. Vaux DL, Aguila HL, Weissman IL. Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell mediated killing. Int. Immunol. 1992; 4: 821-4.
52. Strasser A, Harris AW, Cory S. bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 1991; 67: 889-99.
53. Kitada S, Miyashita T, Tanaka S, Reed JC. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res. Dev. 1993; 3: 157-69.
54. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl Acad. Sci. USA 1991; 88: 6961-5.
55. Kamada S, Shimono A, Shinto Y et al. Bcl-2 deficiency in mice leads to pleiotropic abnormalities: Accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res. 1995; 55: 354-9.
56. Reed JC, Zha H, Aime SC, Takayama S, Wang HG. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv. Exp. Med. Biol. 1996; 406: 99-112.
57. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCLI, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl Acad. Sci. USA 1993; 90: 3516-20.
58. Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis. Science 1986; 234: 364-8.
59. Reynolds JE, Yang T, Qian L et al. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res. 1994; 54: 6348-52.
60. Choi SS, Park IC, Yun JW, Sung YC, Hong SI, Shin HS. A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 1995; 11: 1693-8.
61. Lin EY, Orlofsky A, Berger MS, Prystowsky MB. Characterization of Al, a novel haemopoietic-specific early response gene with sequence similarity to bcl-2. J. Immunol. 1993; 151: 1979-88.
62. Carrio R, Lopez HM, Jimeno J et al. Al demonstrates restricted tissue distribution during embryonic development and functions to protect against cell death. Am. J. Pathol. 1996; 149: 2133-42.
63. Boise LH, Gonzalez-Garcia M, Postema CE et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
64. Oltvai ZN, Millman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
65. Hunter JJ, Parslow TG. A peptide sequence from Bax that converts Bcl-2 into an activator of apoptosis. J. Biol. Chem. 1996; 271: 8521-4.
66. Yin X-M, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 1994; 369: 321-3.
67. Simonian PL, Grillot DA, Andrews DW, Leber B, Nunez G. Bax homodimerization is not required for Bax to accelerate chemotherapy-induced cell death. J. Biol. Chem. 1996; 271: 32 073-7.
68. Antonsson B, Conti F, Ciavatta A et al. Inhibition of Bax channel-forming activity by Bcl-2. Science 1997; 277: 370-2.
69. Muchmore SW, Sattler M, Liang H et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381: 335-41.
70. Cheng EH-Y, Levine B, Boise LH, Thompson CB, Hardwick JM. Bax-independent inhibition of apoptosis by Bcl-xL. Nature 1996; 379: 554-6.
71. Wang K, Yin X-M, Chao DT, Milliman CL, Korsmeyer S. BID: A novel BH3 domain only death agonist. Genes Dev. 1996; 10: 2859-69.
72. L and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-91.
73. Zha J, Harada H, Yang E, Jockel J. Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-xL. Cell 1996; 87: 619-28.
74. Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 1996; 84: 889-97.
75. Tzung SP, Fausto N, Hockenbery DM. Expression of Bcl-2 family during liver regeneration and identification of Bcl-x as a delayed early response gene. Am. J. Pathol. 1997; 150: 1985-95.
76. Haldar S, Jena N, Croce CM. Antiapoptosis potential of bcl-2 oncogene by dephosphorylation. Biochem. Cell Biol. 1994; 72: 455-62.
77. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc. Natl Acad. Sci. USA 1995; 92: 4507-11.
78. Blagosklonny MV, Giannakakou P, el-Deiry WS et al. Raf-1 bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer Res. 1997; 57: 130-5.
79. Wang HG, Miyashita T, Takayama S et al. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 1994; 9: 2751-6.
80. Wang HG, Takayama S, Rapp UR, Reed JC. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc. Natl Acad. Sci. USA 1996; 93: 7063-8.
81. Takayama S, Sato T, Krajewski S et al. Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity. Cell 1995; 80: 279-84.
82. Wang HG, Millan JA, Cox AD et al. R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressible mechanism. J. Cell Biol. 1995; 129: 1103-14.
83. Chen CY, Faller DV. Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene 1995; 11: 1487-98.
84. Gajewski TF, Thompson CB. Apoptosis meets signal transduction: Elimination of a BAD influence (comment). Cell 1996: 87: 589-92.
85. Boyd JM, Gallo GJ, Elangovan B et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 1995; 11: 1921-8.
86. Inohara N, Ding L, Chen S, Nunez G. Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J. 1997; 16: 1686-94.
87. Farrow SN, White JHM, Martinou I et al. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 1995; 374: 731-3.
88. Chittenden T, Flemington C, Houghton AB et al. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J. 1995; 14: 5589-96.
89. Kiefer MC, Brauer MJ, Powers VC et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995; 374: 736-9.
90. Minn AJ, Velez P, Schendel SL et al. Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature 1997; 385: 353-7.
91. Schendel S, Xie Z, Montai MO, Matsuyama S, Montai M. Reed JC. Channel formation by anti-apoptotic protein. Bcl-2. Proc. Natl Acad. Sci. USA 1997; 94: 5113-18.
92. Reed JC. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 1994; 124: 1-6.
93. Tanaka S, Saito K, Reed JC. Structure-function analysis of the Bcl-2 oncoprotein: Addition of a heterologous trans-membrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival. J. Biol. Chem. 1993; 268: 10 920-6.
94. Hennet T, Bertoni G, Richter C, Peterhans E. Expression of BCL-2 protein enhances the survival of mouse fibrosarcoid cells in tumour necrosis factor-mediated cytotoxicity. Cancer Res. 1993; 53: 1456-60.
95. Zhong LT, Sarafian T, Kane DJ et al. bcl-2 inhibits death of central neural cells induced by multiple agents. Proc. Natl Acad. Sci. USA 1993; 90: 4533-7.
96. Baffy G, Miyashita T, Williamson JR, Reed JC. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent haematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J. Biol. Chem. 1993; 268: 6511-19.
97. Boyd JM, Malstrom S, Subramanian T et al. Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins (comments) (erratum appears in Cell 1994; 79: 1120). Cell 1994; 79: 341-51.
98. Weil M, Jacobson MD, Coles HS et al. Constitutive expression of the machinery for programmed cell death. J. Cell Biol. 1996; 133: 1053-9.
99. Ishizaki Y, Cheng L, Mudge AW, Raff MC. Programmed cell death by default in embryonic cells, fibroblasts. and cancer cells. Mol. Biol. Cell 1995; 6: 1443-58.
100. Jacobson MD, Burne JF, Raff MC. Programmed cell death and Bcl-2 protection in the absence of a nucleus. EMBO J. 1994; 13: 1899-910.
101. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993; 75: 229-40.
102. Motoyama N, Wang F, Roth KA et al. Massive cell death of immature haematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995; 267: 1506-10.
103. Alnemri ES, Livingston DJ, Nicholson DW et al. Human ICE CED-3 protease nomenclature (letter). Cell 1996; 87: 171.
104. Cerretti DP, Kozlosky CJ, Mosley B et al. Molecular cloning of the interleukin-1 beta converting enzyme. Science 1992; 256: 97-100.
105. Thornberry NA, Bull HG, Calaycay JR et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992; 356: 768-74.
106. Dinarello CA, Inflammatory cytokines: Interleukin-1 and tumour necrosis factor as effector molecules in autoimmune diseases. Curr. Opin. Immunol. 1991; 3: 941-8.
107. Black RA, Kronheim SR, Sleath PR. Activation of interleukin-1 beta by a co-induced protease. FEBS Lett. 1989; 247: 386-90.
108. Sleath PR, Hendrickson RC, Kronheim SR, March CJ, Black RA. Substrate specificity of the protease that processes human interleukin-1 beta. J. Biol. Chem. 1990; 265: 14526-8.
109. Howard AD, Kostura MJ, Thornberry N et al. IL-1-converting enzyme requires aspartic acid residues for processing of the IL-1 beta precursor at two distinct sites and does not cleave 31-kDa IL-1 alpha. J. Immunol. 1991; 147: 2964-9.
110. Hudig D, Ewoldt GR, Woodard SL. Proteases and lymphocyte cytotoxic killing mechanisms. Curr. Opin. Immunol. 1993; 5: 90-6.
111. Miura M, Friedlander RM, Yuan J. Tumour necrosis factor-induced apoptosis is mediated by a CrmA-sensitive cell death pathway. Proc. Natl Acad. Sci. USA 1995; 92: 8318-22.
112. Margolin N, Raybuck SA, Wilson KP et al. Substrate and inhibitor specificity of interleukin-1 beta-converting enzyme and related caspases. J. Biol. Chem. 1997; 272: 7223-8.
113. Nicholson DW, Ali A, Thornberry NA et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis (comments). Nature 1995; 376: 37-43.
114. Takahashi A, Alnemri ES, Lazebnik YA et al. Cleavage of lamin A by Mch2 alpha but not CPP32: Multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc. Natl Acad. Sci. USA 1996; 93: 8395-400.
115. Rano TA, Timkey T, Peterson EP et al. A combinatorial approach for determining protease specificities: Application to interleukin-1 beta converting enzyme (ICE). Chem. Biol. 1997; 4: 149-55.
116. Ray CA, Black RA, Kronheim SR et al. Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 1992; 69: 597-604.
117. Komiyama T, Ray CA, Pickup DJ et al. Inhibition of interleukin-1 beta converting enzyme by the cowpox virus serpin CrmA: An example of cross-class inhibition. J. Biol. Chem. 1994; 269: 19331-7.
118. Xue D, Horvitz HR, Inhibition of the Caenorhabditis elegans cell-death protease CED-3 by a CED-3 cleavage site in baculovirus p35 protein. Nature 1995; 377: 248-51.
119. Hawkins CJ, Uren AG, Hacker G, Medcalf RL, Vaux DL. Inhibition of interleukin 1 beta-converting enzyme-mediated apoptosis of mammalian cells by baculovirus IAP. Proc. Natl Acad. Sci. USA 1996; 93: 13 786-90.
120. Bump NJ, Hackett M, Hugunin M et al. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science 1995; 269: 1885-8.
121. Clem RJ, Miller LK. Control of programmed cell death by the baculovirus genes p35 and IAP. Mol. Cell. Biol. 1994; 14: 5212-22.
122. Crook NE, Clem RJ, Miller LK, An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J. Virol. 1993; 67: 2168-74.
123. Liston P. Roy N, Tamai K et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996; 379: 349-53.
124. Roy N, Mahadevan MS. McLean M et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy (comments). Cell 1995; 80: 167-78.
125. Tewari M, Dixit VM. Fas- and tumour necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J. Biol. Chem. 1995; 270: 3255-60.
126. Tewari M, Telford WG, Miller RA, Dixit VM. CrmA, a poxvirus-encoded serpin, inhibits cytotoxic T lymphocyte-mediated apoptosis. J. Biol. Chem. 1995; 270: 22 705-8.
127. Wang L, Miura M, Bergeron L, Zhu H, Yuan J. Ich-1, an ICE/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell 1994; 78: 739-50.
128. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extra-cellular matrix. Science 1995; 267: 891-3.
129. Datta R, Kojima H, Banach D et al. Activation of a CrmA-insensitive. p35-sensitive pathway in ionizing radiation-induced apoptosis. J. Biol. Chem. 1997; 272: 1965-9.
130. Strasser A, Harris AW, Huang DCS, Krammer PH, Cory S, Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 1995; 14: 6136-47.
131. Zhou Q, Snipas S, Orth K, Muzio M, Dixit VM, Salvesen GS. Target protease specificity of the viral serpin crmA. J. Biol. Chem. 1997; 272: 7797-800.
132. Tewari M, Quan LT, O'Rourke K et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 1995; 81: 801-9.
133. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994; 371: 346-7.
134. Muzio M, Chinnaiyan AM, Kischkel FC et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817-27.
135. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996; 85: 803-15.
136. Muzio M, Salvesen GS, Dixit VM. FLICE induced apoptosis in a cell-free system: Cleavage of caspase zymogens. J. Biol. Chem. 1997; 272: 2952-6.
137. McKeon F. Nuclear lamin proteins: Domains required for nuclear targeting, assembly, and cell-cycle-regulated dynamics. Curr. Opin. Cell Biol. 1991; 3: 82-6.
138. Heald R, McKeon F. Mutations of phosphorylation sites in lamin A that prevent nuclear lamina disassembly in mitosis. Cell 1990; 61: 579-89.
139. Oberhammer FA, Hochegger K, Froschl G, Tiefenbacher R, Pavelka M. Chromatin condensation during apoptosis is accompanied by degradation of lamin A+B, without enhanced activation of cdc2 kinase. J. Cell Biol. 1994; 126: 827-37.
140. Rao L, Perez D, White E. Lamin proteolysis facilitates nuclear events during apoptosis. J. Cell Biol. 1996; 135: 1441-55.
141. Orth K, Chinnaiyan AM, Garg M, Froelich CJ, Dixit VM. The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J. Biol. Chem. 1996; 271: 16 443-6.
142. McConkey DJ, Calcium-dependent, interleukin 1-converting enzyme inhibitor-insensitive degradation of lamin B1 and DNA fragmentation in isolated thymocyte nuclei. J. Biol. Chem. 1996; 271: 22 398-406.
143. Clawson GA, Norbeck LL, Hatem CL et al. Ca(2+)-regulated serine protease associated with the nuclear scaffold. Cell Growth, Differ. 1992; 3: 827-38.
144. Lazebnik YA, Takahashi A, Moir RD et al. Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Proc. Natl Acad. Sci. USA 1995; 92: 9042-6.
145. L function upstream of the CED-3-like apoptotic proteases. J. Biol. Chem. 1996; 271: 4573-6.
146. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65.
147. Darmon AJ, Bleackley RC. An interleukin-1beta converting enzyme-like protease is a key component of Fas-mediated apoptosis. J. Biol. Chem. 1996; 271: 21 699-702.
148. Srinivasula SM, Fernandes AT, Zangrilli J et al. The Ced-3/ interleukin-1beta converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2alpha are substrates for the apoptotic mediator CPP32. J. Biol. Chem. 1996; 271: 27 099-106.
149. Fernandes AT, Takahashi A, Armstrong R et al. Mch3, a novel human apoptotic cysteine protease highly related to CPP32. Cancer Res. 1995; 55: 6045-52.
150. Fernandes AT, Armstrong RC, Krebs J et al. In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc. Natl Acad. Sci. USA 1996; 93: 7464-9.
151. Enari M, Talanian RV, Wong WW, Nagata S. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996; 380: 723-6.
152. Srinivasula SM, Ahmad M, Fernandes AT, Litwack G, Alnemri ES. Molecular ordering of the Fas-apoptotic pathway: The Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl Acad. Sci. USA 1996; 93: 14 486-91.
153. Faucheu C, Diu A, Chan AW et al. A novel human protease similar to the interleukin-1 beta converting enzyme induces apoptosis in transfected cells. EMBO J. 1995; 14: 1914-22.
154. Berke G. The CTL's kiss of death. Cell 1995; 81: 9-12.
155. Henkart PA, Sitkovsky MV. Cytotoxic lymphocytes: Two ways to kill target cells. Curr. Biol. 1994; 4: 923-5.
156. Tschopp J, Jongeneel CV. Cytotoxic T lymphocyte mediated cytolysis. Biochemistry 1988; 27: 2641-6.
157. Renner C, Held G, Ohnesorge S et al. Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated Cytotoxic T cells. Cancer Immunol. Immunother. 1997; 44: 70-6.
158. Poe M, Blake JT, Boulton DA et al. Human Cytotoxic lymphocyte granzyme B: Its purification from granules and the characterization of substrate and inhibitor specificity. J. Biol. Chem. 1991; 266: 98-103.
159. Chinnaiyan AM, Hanna WL, Orth K et al. Cytotoxic T cell-derived granzyme B activates the apoptotic protease ICE-LAP3. Curr. Biol. 1996; 6: 897-9.
160. Quan LT, Caputo A, Bleackley RC, Pickup DJ, Salvesen GS, Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A. J. Biol. Chem. 1995; 270: 10 377-9.
161. Chinnaiyan AM, O'Rourke K, Lane BR, Dixit VM. Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death (comments). Science 1997; 275: 1122-6.
162. Spector MS, Desnoyers S, Hoeppner DJ, Hengartner MO. Interaction between the C. elegans cell-death regulators CED-9 and CED-4. Nature 1997; 385: 653-6.
163. Wu D, Wallen HD, Nunez G. Interaction and regulation of subcellular localization of CED-4 by CED-9 (comments). Science 1997; 275: 1126-9.
164. Hofmann K, Bucher P, Tschopp J. The CARD domain: A new apoptotic signalling motif. Trends Biochem. Sci. 1997; 22: 155-6.
165. Vaux DL. CED-4: The third horseman of apoptosis. Cell 1997; 90: 389-90.
166. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 1996; 86: 147-57.
167. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6.
168. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 1993; 361: 365-9.
169. Gonzales DH, Neupert W. Biogenesis of mitochondrial c-type cytochromes. J. Bioenerg. Biomembr. 1990; 22: 753-68.
170. Yang J, Liu X, Bhalla K et al. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked (comments). Science 1997; 275: 1129-32.
171. Kluck RM, Bossy WE, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis (comments). Science 1997; 275: 1132-6.
172. Oehm A, Behrmann I. Falk W et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumour necrosis factor/nerve growth factor receptor superfamily: Sequence identity with the Fas antigen. J. Biol. Chem. 1992; 267: 10 709-15.
173. Pan G, O'Rourke K, Chinnaiyan AM et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-13.
174. Itoh N, Nagata S. A novel protein domain required for apoptosis: Mutational analysis of human Fas antigen. J. Biol. Chem. 1993; 268: 10 932-7.
175. Tartaglia LA. Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74: 845-53.
176. Stanger BZ, Leder P, Lee TH, Kim K, Seed B. RIP: A novel protein containing a death domain that interacts with Fas/ APO-1 (CD95) in yeast and causes cell death. Cell 1995; 81: 513 23.
177. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449 56.
178. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumour necrosis factor cytokine family. J. Biol. Chem. 1996; 271: 12 687 90.
179. Gearing AJ, Beckett P, Christodoulou M et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994; 370: 555-7.
180. Tanaka M, Suda T, Haze K et al. Fas ligand in human serum. Nat. Med. 1996; 2: 317-22.
181. Tanaka M. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J. Immunol. 1997; 158: 2303-9.
182. Androlewicz MJ, Browning JL, Ware CF. Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma. J. Biol. Chem. 1992; 267: 2542-7.
183. Mariani SM, Matiba B, Armandola EA, Krummer PH. Interleukin 1β-converting enzyme related proetases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukaemia cells. J. Cell Biol. 1997; 137: 221-9.
184. Loetscher H, Pan YC, Lahm HW et al. Molecular cloning and expression of the human 55 kd tumour necrosis factor receptor. Cell 1990; 61: 351-9.
185. Osborne L, Kunkel S, Nabel GJ. Tumour necrosis factor-α and interleukin 1 stimulate the human immunodeficiency enhancer by activation of the nuclear factor κb. Proc. Natl Acad. Sci. USA 1989; 86: 2336-40.
186. Brenner DA. O'Hara M, Angel P, Chojkier M, Karin M. Prolonged activation of jun and collagenase genes by tumour necrosis factor, Nature 1989; 337: 661-3.
187. Wong GH, Tartaglia LA, Lee MS, Goeddel DV. Antiviral activity of tumour necrosis factor is signaled through the 55-kDa type 1 TNF receptor (erratum appears in J. Immunol. 1993; 150: 705). J. Immunol. 1992; 149: 3350-3.
188. Thome M, Schneider P, Hofman K et al. Viral FLICE-inhibitory proteins (FL1Ps) prevent apoptosis induced by death receptors. Nature 1997; 386: 517-21.
189. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-5.
190. Green DR, Ware CF, Fas-ligand: Privilege and peril. Proc. Natl Acad. Sci. USA 1997; 94: 5986-90.
191. Singer GG, Abbas AK. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994; 1: 365-71.
192. + T cells responding to a bacterial superantigen. J. Immunol. 1995; 154: 4302-8.
193. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA, CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996; 5: 7-16.
194. Bellgrau D, Gold D, Selawry H, Moore J. Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection (comments). Nature 1995; 377: 630-2.
195. Watanabe FR, Brannan CI. Itoh N et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 1992; 148: 1274-9.
196. Ogasawara J, Watanabe FR, Adachi M et al. Lethal effect of the anti-Fas antibody in mice (published erratum appears in Nature 1993; 365: 568). Nature 1993; 364: 806-9.
197. Braun MY, Lowin B, French L, Acha OH, Tschopp J. Cytotoxic T cells deficient in both functional las ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-vs.-host disease. J. Exp. Med. 1996; 183: 657-61.
198. Abreu MM, Vidrich A, Lynch DH, Targan SR. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J. Immunol. 1995; 155: 4147-54.
199. Manome Y, Weichselbaum RR, Kufe DW, Fine HA. Effect of Bcl-2 on ionizing radiation and 1-beta-D-arabinofuranosylcytosine-induced internucleosomal DNA fragmentation and cell survival in human myeloid leukaemia cells. Oncol. Res. 1993; 5: 139-44.
200. Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 1992; 52: 5407-11.
201. Memon SA, Moreno MB, Petrak D, Zacharchuk CM. Bcl-2 blocks glucocorticoid- but not Fas- or activation-induced apoptosis in a T cell hybridoma. J. Immunol. 1995; 155: 4644-52.
202. Vaux DL, Whitney D, Weissman IL, Activation of physiological cell death mechanisms by a necrosis-causing agent. Microsc. Res. Tech. 1996; 34: 259-66.
203. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair (erratum appears in Cancer Res. 1994; 54: 3074). Cancer Res. 1993; 53: 4251-6.
204. Jacobson MD, Raff MC. Programmed cell death and Bcl-2 protection in very low oxygen. Nature 1995; 374: 814-16.
205. Campos L, Rouault JP, Sabido O et al. High expression of bcl-2 protein in acute myeloid leukaemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-6.
206. Lin KI, Lee SH, Narayanan R, Baraban JM, Hardwick JM, Ratan RR. Thiol agents and Bcl-2 identify an alphavirus-induced apoptotic pathway that requires activation of the transcription factor NF-kappa B. J. Cell Biol. 1995; 131: 1149-61.
207. Armstrong RC, Aja T, Xiang J et al. Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. J. Biol. Chem. 1996; 271: 16 850-5.
208. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359: 552-4.
209. Wang Y, Szekely L, Okan I, Klein G, Wiman KG. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T cell lymphoma line. Oncogene 1993; 8: 3427-31.
210. Okazawa H, Shimizu J, Kamei M, Imafuku I, Hamada H, Kanazawa I. Bcl-2 inhibits retinoic acid-induced apoptosis during the neural differentiation of embryonal stem cells. J. Cell Biol. 1996; 132: 955-68.
211. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 1994; 124: 619-26.
212. Debatin KM, Krammer PH. Resistance to APO-I (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. Leukaemia 1995; 9: 815-20.
213. Cuende E, Ales MJ, Ding L, Gonzalez GM, Martinez C, Nunez G. Programmed cell death by bcl-2-dependent and independent mechanisms in B lymphoma cells. EMBO J. 1993; 12: 1555-60.
214. Sato T, Hanada M, Bodrug S et al. Interactions among members of the Bcl-2 protein family analysed with a yeast two-hybrid system (erratum appears in Proc. Natl Acad. Sci. USA 1995; 92: 2016). Proc. Natl Acad. Sci. USA 1994; 91: 9238-42.
215. Sedlak TW, Oltvai ZN, Yang E et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc. Natl Acad. Sci. USA 1995; 92: 7834-8.
216. Zhang H, Saeed B, Ng SC. Combinatorial interaction of human bcl-2 related proteins: Mapping of regions important for bcl-2/bcl-x-s interaction. Biochem. Biophys. Res. Commun. 1995; 208: 950-6.
217. Kurschner C, Morgan JI. The cellular prion protein (PrP) selectively binds to Bcl-2 in the yeast two-hybrid system. Brain Res. Mol. Brain Res. 1995; 30: 165-8.
218. Fernandez SM, Bischoff JR. Bcl-2 associates with the ras-related protein R-ras p23. Nature 1993; 366: 274-5.
219. Chen CY, Faller DV. Phosphorylation of Bcl-2 protein and association with p21Ras in Ras-induced apoptosis. J. Biol. Chem. 1996; 271: 2376-9.